Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

High dose intravenous immunoglobulin does not affect complement-bacteria interactions

E Wagner1, J L Platt, M M Frank

  • 1Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA.

Journal of Immunology (Baltimore, Md. : 1950)
|February 20, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dual disorder: does expert clinical experience support the rationale for cariprazine use?

European review for medical and pharmacological sciences·2024
Same author

Optimising plasma clozapine levels to improve treatment response: an individual patient data meta-analysis and receiver operating characteristic curve analysis.

The British journal of psychiatry : the journal of mental science·2023
Same author

Incidence of tick-borne spotted fever group Rickettsia species in rodents in two regions in Kazakhstan.

Scientific reports·2022
Same author

Genome-wide association analyses of symptom severity among clozapine-treated patients with schizophrenia spectrum disorders.

Translational psychiatry·2022
Same author

[Radiological and functional results in high-energy tibial plate fractures].

Acta ortopedica mexicana·2022
Same author

The sodium iodide symporter (NIS): novel applications for radionuclide imaging and treatment.

Endocrine-related cancer·2021
Same journal

Crystal structure and immune single-cell atlas provide insights into the functional divergence of type I IFNs in fish.

Journal of immunology (Baltimore, Md. : 1950)·2026
Same journal

Complement C3 deficiency increases the effector and cytotoxic functions of NK cells and suppresses tumor growth.

Journal of immunology (Baltimore, Md. : 1950)·2026
Same journal

Increased Nur77 is disconnected from TCR affinity in insulin-specific Tregs.

Journal of immunology (Baltimore, Md. : 1950)·2026
Same journal

FTR85 negatively regulates type I IFN antiviral signaling pathway by promoting K48-linked polyubiquitination of IRF3.

Journal of immunology (Baltimore, Md. : 1950)·2026
Same journal

An MR1-specific nanobody capable of blocking MR1T cell activation.

Journal of immunology (Baltimore, Md. : 1950)·2026
Same journal

TGF-β controls developmental fate and functional identity of thymic γδ T cells.

Journal of immunology (Baltimore, Md. : 1950)·2026
See all related articles

Pooled IgG preparations for intravenous use (IVIg) do not hinder the complement system

Area of Science:

  • Immunology
  • Microbiology

Background:

  • Intravenous immunoglobulin (IVIg) preparations exhibit anticomplementary activity, diverting complement activation from target surfaces in autoimmune and inflammatory diseases.
  • IVIg acts as a preferential acceptor of activated complement components C4 and C3.

Purpose of the Study:

  • To investigate the impact of IVIg on complement-bacteria interactions.
  • To assess the safety of IVIg concerning natural immunity against bacteria.
  • To deepen the understanding of IVIg's physiological mechanisms of action.

Main Methods:

  • Evaluation of IVIg's effect on C3 binding to bacterial surfaces using complement-sensitive and -resistant strains.
  • Assessment of IVIg's influence on complement-dependent bacterial lysis.
  • Analysis of C1q binding to bacteria in the presence of varying IVIg concentrations.

Related Experiment Videos

  • Examination of complement binding and lysis of bacteria in patient serum samples post-IVIg treatment.

    • Main Results:

    • IVIg did not alter C3 binding to bacterial surfaces, irrespective of the complement activation pathway (classical or alternative).
    • IVIg did not inhibit complement-dependent bacterial lysis.
    • Increased IVIg concentrations correlated with enhanced C1q binding, suggesting potential low-affinity antibacterial antibodies in some IVIg preparations.
    • Serum from IVIg-treated patients showed no change in complement-mediated bacterial lysis or binding compared to controls, despite reduced C3 binding to sensitized erythrocytes.

    Conclusions:

    • IVIg does not interfere with direct complement-bacteria interactions.
    • IVIg is effective in diverting complement activation from sensitized target surfaces.
    • The safety of IVIg regarding natural antibacterial immunity appears maintained.